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SAG/RBX2/ROC2 protein is an essential RING
component of SCF E3 ubiquitin ligase. The role of
SAG during embryogenesis remains unknown. We
report a critical role for SAG in controlling vascular
and neural development by modulating RAS activity
via promoting degradation of neurofibromatosis
type 1 (NF1). Mice mutant for Sag died at embryonic
day 11.5–12.5 with severe abnormalities in vascular
and nervous system. Sag inactivation caused Nf1
accumulation and Ras inhibition, which blocks
embryonic stem (ES) cells from undergoing endothe-
lial differentiation and inhibits angiogenesis and
proliferation in teratomas. Simultaneous Nf1 deletion
fully rescues the differentiation defects in Sag/ ES
cells and partially rescues vascular and neural
defects in Sag/ embryos, suggesting that the
effects of Sag deletion may not be solely explained
by Nf1 misregulation. Collectively, our study iden-
tifies NF1 as a physiological substrate of SAG-
CUL1-FBXW7 E3 ligase and establishes a ubiquitin-
dependent regulatory mechanism for the NF1-RAS
pathway during embryogenesis.
INTRODUCTION
The SCF E3 ubiquitin ligase is the largest family of E3 ligases,
consisting of SKP1, Cullins, F-box proteins, and a RING protein,
RING box protein-1 (RBX), also known as regulators of Cullins
(ROC). The substrate specificity of SCF complex is determined
by the F box proteins that bind to SKP1 and Cullins through its
F-box domain and to substrates through its WD40 or LRR
domains (Jin et al., 2004; Zheng et al., 2002), whereas the core
SCF E3 ubiquitin ligase is a complex of Cullins-RBX, in which
RBX binds to E2 and facilitates ubiquitin transfer from E2 to
the substrates (Wu et al., 2000). By promoting the ubiquitination
of various regulatory proteins for degradation by 26S protea-1062 Developmental Cell 21, 1062–1076, December 13, 2011 ª2011some, SCF ligases regulate many biological processes, in-
cluding apoptosis, cell cycle progression, signal transduction
and DNA replication (Deshaies and Joazeiro, 2009; Nakayama
and Nakayama, 2006). Although a large number of F-box
proteins were found in the human genome (Jin et al., 2004) that
selectively target various protein substrates, there are only two
family members of RING proteins in human or mouse, RBX1
and RBX2, also known as sensitive to apoptosis gene (SAG)
(Duan et al., 1999; Kamura et al., 1999; Ohta et al., 1999; Tan
et al., 1999; Wei and Sun, 2010). Both family members, having
a functional RING domain at the carboxyl terminus, are evolu-
tionally conserved with a similar tissue expression pattern (Sun
et al., 2001). Although either RBX1 or SAG is capable of binding
to six members of cullin family (CUL 1-3, CUL4A, B, and CUL-5)
and has in vitro E3 ubiquitin ligase activity when complexed with
cullin-1 (Furukawa et al., 2002; Swaroop et al., 2000), RBX1 is
constitutively expressed and prefers to bind with CUL2/VHL,
whereas SAG is stress-inducible and preferably binds to
CUL5/SOCS (Gu et al., 2007a; Kamura et al., 2004).
The role of SAG during development has been previously
studied in several model organisms. The Hrt1, the only yeast
homolog of RBX1/SAG, is a growth-essential gene whose
targeted disruption causes yeast death, which can be fully
rescued by either human RBX1 (Ohta et al., 1999; Seol et al.,
1999) or SAG (Swaroop et al., 2000). In Caenorhabditis elegans,
siRNA knockdown of Rbx1 (ZK287.5) induced the death during
embryogenesis as well as in adult animals (Jia et al., 2011; Sasa-
gawa et al., 2003), whereas knockdown of Rbx2/Sag (R10A10.2)
did not cause any significant phenotypic changes (Moore and
Boyd, 2004). InDrosophila, disruption ofRoc1a orRoc1b caused
lethality or male sterility, respectively, whereas disruption of
Roc2/Sag caused no overt developmental phenotype (Donald-
son et al., 2004; Reynolds et al., 2008). These studies suggest
that RBX2 homologs in C. elegans and Drosophila are function-
ally redundant and RBX2 loss can be compensated by its family
member, RBX1 or ROC1a/1b during embryogenesis. Our recent
knockout study revealed that the in vivo functions of Rbx1 and
Sag are nonredundant in mice. In Sag wild-type background,
the Rbx1 inactivation caused early embryonic lethality at embry-
onic day 7.5 (E7.5) due to proliferation defects, which is partially
caused by p27 accumulation, as simultaneous deletion of p27Elsevier Inc.
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E9.5. Thus, one in vivo physiological function of Rbx1 is to ensure
cell proliferation by preventing p27 accumulation during the early
stage of embryogenesis (Tan et al., 2009). However, the role of
Sag during mouse embryogenesis is unknown.
TheNF1 tumor suppressor gene is frequently mutated inmany
types of sporadic human cancers including glioblastoma multi-
forme, malignant peripheral nerve sheath tumor and epithelial
cancers in the ovary and lung (Ding et al., 2008; Parsons et al.,
2008; Sangha et al., 2008; Cancer Genome Atlas Research
Network, 2008; Woodruff, 1999). Individuals with NF1 mutations
are predisposed to developing a variety of benign and malignant
tumors, many of which affect the peripheral and central nervous
system (Cichowski and Jacks, 2001). NF1 contains a functional
domain that shows homology to the members of the RAS
GTPase activating protein (GAP) family. As a GAP, NF1 nega-
tively regulates RAS proto-oncogene by accelerating the con-
version of active RAS-GTP to inactive RAS-GDP (Le and Parada,
2007). Upon growth factor stimulation, NF1 is rapidly degraded
by the ubiquitin-proteasome pathway (Cichowski et al., 2003;
McGillicuddy et al., 2009) to ensure a proper activation of RAS
signals for proliferation. Previous studies on NF1 ubiquitination
and degradation only focused on its GAP-related domain
(GRD). One study found that a fragment containing NF1 GRD
domain and its adjacent 80 amino acids (codons 1096–1534)
was degradation-sensitive, but did not identify corresponding
E3 ubiquitin ligase (Cichowski et al., 2003). A recent study
reported that ETEA, a UBA and UBX domains-containing
protein, bound to NF1 GRD domain, and negatively regulated
NF1 levels (Phan et al., 2010). However, ETEA is not a bona
fide E3 ubiquitin ligase. Thus, the E3 ubiquitin ligase responsible
for targeted degradation of NF1 remains unknown.
In this study, we used a knockout approach and revealed the
critical roles of Sag in embryonic vascular and neural develop-
ment, and endothelial differentiation of ES cells. We found that
Sag disruption caused Nf1 accumulation to inhibit Ras-Mapk
signals. Simultaneous Nf1 deletion rescues the defects fully in
endothelial differentiation of Sag/ ES cells and partially in
developing vascular and nervous system of Sag/ embryos,
suggesting Nf1 misregulation contributes partly to the defects
derived fromSag deletion.We further showed that NF1 is a phys-
iological substrate of SAG-CUL1-FBXW7 E3 ubiquitin ligase.
Upon recognized and bound by FBXW7, NF1 is targeted for
ubiquitination and degradation by SAG E3. Thus, our study re-
veals the mechanisms that regulate the stability of NF1 proteins,
which might provide insights on designing novel therapy for
NF1-related diseases.
RESULTS
The Sag Disruption Causes Embryonic Death
at E11.5–12.5
To understand the in vivo physiological function(s) of SAG, we
inactivated Sag in mice via a gene-trap approach. Mouse Sag
(NM_011279) wasmapped onto chromosome 9with three exons
and two introns (see Figure S1A available online). One ES clone
(XE423) with a gene-trap vector inserted in the second intron of
the Sag gene was identified (Nord et al., 2006) and characterized
by PCR genome walking (Figure S1A). The insertion disrupts theDevelopmentaSag transcript resulting in a truncated fusionmRNA that encodes
partial Sag N-terminal sequence without the RING domain and
Sag function (Sun, 1999). The confirmed ES clone was injected
into C57BL/6 blastocysts to obtain chimeras, which were back-
crossed with C57BL/6 mice to obtain germline transmission.
Offspring carrying the Sag genetrap allele were identified by
PCR genotyping (Figure S1B), and further confirmed by genomic
Southern blot analysis (Figures S1C and S1D). Expression of Sag
protein in Sag+/+, but not in Sag/ embryos was detected at
E10.5 (Figure S1E).
Intercrossing of heterozygous mice, which survived to term
without any observable abnormalities, failed to generate Sag-
disrupted homozygous mice among a total of 624 genotyped
offspring. The ratio of wild-type mice to heterozygous mice
was about 1:2, exactly as expected for a condition with homozy-
gous lethal phenotype (Figure S1F). To define at which stage of
development the Sag/ embryos die, we dissected uteri of
pregnant mice between E9.5 and E15.5. No viable Sag/
embryos were detected after E13.5 days, whereas a few viable
Sag/ embryos were detected at E11.5–12.5 with reduced fre-
quency. At E9.5–10.5, a Mendelian ratio of 1:2:1 (+/+:+/:/)
was observed (Figure S1F). Thus, homozygous deletion of Sag
causes embryonic lethality at E11.5–12.5.
The Sag Disruption Causes Vascular Defects in Yolk
Sacs and Embryos
Dissection of Sag/ embryos at E10.5 revealed that Sag/
embryos were growth-retarded with frequent pericardial edema
(Figure 1A, arrow). Furthermore, the yolk sacs ofSag/ embryos
have dramatic reduction of blood vessels, which was confirmed
by CD31/PECAMwhole-mount staining for endothelial cells (Fig-
ure 1B). Compared to Sag+/+ embryos with extensive vascular
network of both large and small vessels in the head region (Fig-
ure 1C), Sag/ embryos exhibited disrupted vasculature with
missing major blood vessels and disorganized secondary
branches (Figure 1D). Similar vascular defects were also found
inSag/E9.5 embryos (data not shown). Hematoxylin and eosin
(H&E) stained sagittal sections revealed a substantial reduction
in blood vessels and the number of nucleated red blood cells
within blood islands in the yolk-sac of Sag/ embryos (Fig-
ure 1E, top). Vascular defects in the head region were also
evident with a reduction in the number of blood vessels sur-
rounding and within the neuroepithelium (Figures 1E and 1F).
The Sag Disruption Abrogates Endothelial
Differentiation of ES Cells and Inhibits Teratoma
Growth and Angiogenesis
To dissect the underlying mechanisms responsible for the
observed vascular defects in Sag/ embryos, we turned into
an in vitro cell culture system to circumvent early lethality caused
by Sag deficiency. We generated Sag/ embryonic stem (ES)
cells from blastocysts, obtained from Sag+/ intercrosses.
Sag+/+ ES cells underwent endothelial differentiation to form
cystic embryoid bodies (cEBs) (Figure 2A) with blood island
structures, lined with endothelial cells (Figure 2B, arrows). In
contrast, Sag/ ES cells completely failed to differentiate into
cEBs, although they did form EBs (Figures 2A and 2B). These
results suggest that Sag is required for EBs to undergo endo-
thelial differentiation to form cEBs under in vitro culturedl Cell 21, 1062–1076, December 13, 2011 ª2011 Elsevier Inc. 1063
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Figure 2. Sag Disruption Inhibits ES Cell Endothelial Differentiation
In Vitro and Teratoma Formation In Vivo
(A and B) Endothelial differentiation of embryoid bodies: ES cells underwent
endothelial differentiation for indicated periods and photographed. Arrows
indicate cystic EBs that occurred in Sag+/+ ES cells only (A). The EBs were
whole-mounted with CD31, and counterstained with eosin (2003) (B).
(C–F) Growth and angiogenesis of teratomas. Two pairs of ES cell lines,
AB2/CA2 (Sag+/+) versus AB1/CB1 (Sag/) (C), top) were injected into nude
mice (seven per group). Tumor growth was monitored for 23 days. The mean
tumor volume (mm3) of seven tumors (except AB1 line with two tumors gen-
erated) was plotted (mean ± SEM, *p = 0.0044, between AB1/CB1 and
AB2/CA2, using an F-test from the mixed model) (C, bottom). Tumor sections
were immunostained with CD31 for microvessels (D), and were quantified in
multiple representative areas of at least two tumors (mean ± SEM; *p = 0.0117)
(E). Mice were injected with BrdU and tumor tissues were processed for BrdU
staining. BrdU positive cells (blue) were counted in multiple areas (mean ±
SEM; **p = 0.0002) (F). See also Figure S2.
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Figure 1. Sag Inactivation Disrupts Vascular Development in Yolk-
Sac and Embryo Brains
(A) Appearance of mouse embryos at E10.5 with (left) and without (right) yolk-
sacs. Arrow points to pericardial edema. Scale bar represents 0.75 mm.
(B) Appearance of mouse yolk sac at E10.5 after whole-mount staining with
CD31. Scale bar represents 1 mm.
(C and D) Appearance of mouse embryo brain regions at E10.5 after whole-
mount CD31 staining of embryos. Scale bar represents 3 mm.
(E) Reduced number of blood vessels in Sag/ embryos. Hematoxylin and
eosin stained embryo sections of Sag+/+ (Ea, Ec) and Sag/ (Eb, Ed) at E10.5.
* indicates network of small blood vessels with cellular contents. Arrow heads
indicate blood vessels (Ec, Ed) around brain region. Insets indicate number
and size of blood vessels (*) within neuroepithelium. Number of blood vessels
around the entire brain region was counted (bars, SEM, n = 5 counted areas).
(F) Data were plotted. **p = 0.00269. See also Figure S1.
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of teratoma derived from ES cells upon injected into
nude mice. We used two independent pairs of Sag/ versus
Sag+/+ ES cells and found that teratomas derived from Sag/
ES cells grew much slower and formed significantly smaller
tumors with a lower tumor incidence (AB1 teratomas developed
in 2 out of 7 mice) (Figure 2C; Figure S2A). Teratomas derived
from Sag/ ES cells also had a significantly reduced blood
vessel density (Figures 2D and 2E). Immunocostaining experi-
ment revealed that these blood vessels were derived from trans-
planted ES cells, not from host progenitor cells, because the
endothelial cells coexpressed both CD31 and b-gal (targeting
vector contains b-gal cDNA) in teratomas derived from Sag/,
but not from Sag+/+ ES cells (Figure S2B). Furthermore, we
observed a reduced proliferation rate in teratomas from Sag/
ES cells, compared to those from Sag+/+ ES cells (Figure 2F).1064 Developmental Cell 21, 1062–1076, December 13, 2011 ª2011Thus, Sag disruption remarkably inhibits angiogenesis and
growth/proliferation of teratomas in vivo.
Sag Is Required for Active Ras/Mapk Signals during
Endothelial Differentiation and Teratoma Proliferation
Because RAS/MAP kinase pathways are known to regulate
proliferation, angiogenesis, and endothelial cell differentiationElsevier Inc.
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Figure 3. Sag Disruption Causes Inactivation of Ras/Mapks and Accumulation of Nf1
(A and B) ES cells were cultured without LIF in static suspension to induce the formation of EBs and cystic EBs up to 13 days. The EBs were lysed for
immunoblotting (IB) (A) or assayed for Ras activity (B).
(C and D) ES cells were differentiated for 13 days in the absence or presence (days 2–4) of FTI277 (1 mM), and lysed for IB (C) or photographed to show cystic EBs
(arrows) (D, left). The % of cEBs in a total of 300 EBs was plotted, mean ± SD (n = 3) (D, right).
(E) Inhibition of Erk phosphorylation. Independent teratoma tissues derived from Sag/ or Sag+/+ ES cells were homogenized for IB.
(F) Nf1 accumulation in Sag/ EBs. ES cells and EBs (differentiated for up to 6 days) were lysed for IB.
(G) No change in Nf1 mRNA during ES cell differentiation. ES or EBs were collected at indicated time points for RT-PCR analysis.
(H) Nf1 accumulation in Sag/ MEFs. Primary MEFs were prepared from E10.5 embryos for IB. See also Figure S3.
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determine whether the Ras signaling pathway is inactivated
during Sag/ ES cell differentiation. As shown in Figure 3A,
phosphorylation of p44/Erk1 was significantly induced during
differentiation of Sag+/+ EBs, but not in Sag/ EBs. No differ-
ence was seen in the levels of total or phosphorylated forms of
Akt and p38. A Ras activity assay further showed that Ras was
active in ES cells, regardless of Sag status, but was completelyDevelopmentainactive in EBs derived from Sag/ ES cells (Figure 3B). Similar
results were obtained from another independent set of ES clones
(data not shown). Thus, Ras activation and Erk1 phosphorylation
were maintained during cystic EB formation, whereas they were
inactivated in the absence of Sag. We further found that FTI277,
an inhibitor of Ras farnesyltransferase (Kawasaki et al., 2008)
that inhibited p44/Erk1 phosphorylation (Figure 3C), could
significantly reduce cystic EB formation from Sag+/+ ES cellsl Cell 21, 1062–1076, December 13, 2011 ª2011 Elsevier Inc. 1065
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Figure 4. FBXW7 and SAG Bind to NF1 and Promote Its Ubiquitination
(A–C) SAG-FBXW7-NF1 forms a complex in vivo. The 293 cells were transfected and treated with MG-132 (10 mM) 4 hr prior to harvesting. Cell lysates were
immunoprecipitated (IP) with bead-conjugated FLAG or HA Abs, followed by IB. The bottom panels are the direct IB using WCE (whole cell extract) as input.
(D) Endogenous FBXW7-NF1 binding: Cell lysates from 293 cells were immunoprecipated using Ab against NF1 (top) or FBXW7 (bottom), along with normal IgG
control, followed by IB. Direct IB was performed using WCE.
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SAG Degrades NF1 to Regulate Embryogenesis(Figure 3D). A similar result was obtained with PD98059, a Mek
inhibitor (Figure S3). Consistently, a reduced Erk phosphoryla-
tion, an indicator of Mek inactivation, was found in Sag/ tera-
toma tissues, as compared to Sag+/+ teratomas (Figure 3E).
Taken together, the findings demonstrated that the inability
to maintain active Ras/Erk signals, upon Sag disruption, con-
tributes significantly to the failure of endothelial differentiation
in vitro, angiogenesis, and possibly reduced proliferation in
teratomas in vivo.
Accumulation of Neurofibromin during ES Cell
Differentiation and in MEFs upon Sag Disruption
RAS signaling pathways are inhibited by naturally occurring
inhibitory proteins or inactivating phosphatases (Karnoub and
Weinberg, 2008; Kolch, 2005). These proteins, upon Sag disrup-
tion, would accumulate to inactivate the RAS pathway during
endothelial differentiation if they were the direct substrates of
SAG-SCF E3 ubiquitin ligases. We therefore examined the levels
of several Ras signaling inhibitory proteins in ES cells and in EBs
formed during differentiation. As shown in Figure 3F, the basal
level of neurofibromin (encoded by Nf1) was slightly higher in
Sag/ ES cells than that in Sag+/+ ES cells. The neurofibromin
(Nf1) level gradually increased, reaching the peak at day 6 of
Sag/ EB differentiation, but remained low in Sag+/+ EBs. No
significant difference was observed between the two groups in
the levels of p120RasGap, a family member of Nf1 with a similar
Ras inhibiting activity (Henkemeyer et al., 1995), nor of other
Ras/Raf inhibitors or phosphatases of the Ras pathway tested
(Dhillon et al., 2007b; Kolch, 2005), including Spred2, Mkp-1,
and PP-2A (subunits B and C), except Rkip, a Raf inhibitor
(Hagan et al., 2006), which showed higher levels in Sag+/+ ES
cells and EBs, but was not regulated by ES cell differentiation
(Figure 3F). RT-PCR analysis revealed that Nf1 mRNA remained
consistent during ES cell differentiation, regardless of Sag status
(Figure 3G), indicating that Nf1 accumulation upon Sag dis-
ruption likely results from a reduced degradation. We further
measured the Nf1 levels in mouse embryonic fibroblasts (MEF)
derived from E10.5 embryos with three Sag genotypes and
found an elevated Nf1 level in Sag/ MEFs, as compared to
that in Sag+/+ or Sag+/ MEFs (Figure 3H). Taken together, our
results suggested that Nf1 could be a substrate of Sag-SCF E3
ubiquitin ligase, which accumulates upon Sag disruption, to
inhibit Ras/Erk signals.
SAG-CUL1-FBXW7 Binds to NF1 and Promotes
Its Ubiquitination
The crystal structure of SCF complex (Zheng et al., 2002) reveals
that the substrate is recognized and recruited by an F-box
protein to the ligase complex for ubiquitination. Thus, Sag-
mediated Nf1 degradation must involve an F-box protein that
recognizes Nf1 for binding. Examination of the NF1 sequence(E and F) NF1-FBXW7 binding and NF1 ubiquitination: FLAG-tagged NF1-C and
MG-132 (10 mM) 4 hr before harvesting for (E) IP with FLAG and IB with FLAG o
endogenous (top) and exogenously expressed NF1-C (bottom), or with FLAG for
(G and H) CUL1-FBXW7 or CUL5-FBXW7 promotes NF1 ubiquitination in vitro: SC
FBXW7 (G) or CUL5 and FBXW7 (H). NF1 substrate was prepared by transfectin
elution. SCF E3 and NF1-C substrates were added into a reaction mixture contain
mixture after 60 min incubation was subjected to IB using c-Myc-tag Ab. * deno
Developmentafor the consensus binding motifs of several F-box proteins
revealed an evolutionarily conserved perfect binding site for
FBXW7 (also known as CDC4) (L-I/L/P-pT-P-XXXX) at the
C terminus (Figure S4A), which is consistent with the binding
motif found in other known substrates of FBXW7 (Figure S4B).
No FBXW7 binding site was identified in p120RasGAP, a family
protein not subject to proteasome-dependent proteolysis
(Cichowski et al., 2003). We therefore determined the potential
binding of FBXW7 and NF1. Using an immunoprecipitation
assay, we found that transiently transfected FBXW7 pulled
down endogenous NF1 (Figure 4A). In a reciprocal experiment,
NF1-C, a C-terminal portion of NF1 (codons 2180–2840) contain-
ing the FBXW7 binding site, pulled down both FBXW7 and SAG
when cotransfected, indicating in vivo binding of SAG-FBXW7-
NF1 (Figure 4B). Furthermore, SAG, when cotransfected with
FBXW7, pulled down FBXW7, as well as endogenous NF1 and
CUL1 (Figure 4C), indicating an in vivo formation of SAG-
CUL1-FBXW7 E3 ligase. More significantly, SAG cotransfection
promoted FBXW7-mediated ubiquitination of endogenous NF1,
as demonstrated by slower migrating bands (Figure 4C, top),
which was not observed when FBXW7 was transfected alone
(Figure 4A, top). In order to detect endogenous FBXW7-NF1
binding, we examined several commercially available antibody
against FBXW7 and identified one from Sigma that was capable
of detecting overexpressed FBXW7 (data not shown). Using this
antibody, we were able to detect endogenous FBXW7-NF1
binding, as evidenced by detection of FBXW7 (likely being
enriched when complexed with NF1) in NF1 immunoprecipitates
(Figure 4D, top panels). Reciprocally, NF1 can also be detected
in FBXW7 immunoprecipitates (Figure 4D, bottom panels).
We next determined if FBXW7-NF1 binding and NF1 ubiq-
uitination were dependent on the FBXW7 consensus-binding
motif on NF1. We generated two NF1 mutants on the FBXW7
binding motif (Figure S4C) and found that these mutations had
a significant reduction in binding to FBXW7 (Figure 4E). Con-
sequently, FBXW7-induced ubiquitination of exogenously ex-
pressed NF1-C was remarkably inhibited in these mutants,
without affecting ubiquitination of endogenous NF1 (Figure 4F).
We further determined NF1 ubiquitination using an in vitro puri-
fied system and found that FBXW7-CUL1 promoted NF1 ubiq-
uitination in a manner dependent on E2 ubiquitin conjugating
enzyme (Figure 4G). The involvement of CUL1 in promoting
NF1 ubiquitination was further demonstrated as follows: (1) en-
dogenous NF1 could be pulled down by exogenously expressed
CUL1 (Figure S4D), (2) siRNA knockdown of CUL1 significantly
inhibited NF1 ubiquitination (Figure S4E), and (3) endogenous
SKP1 were present in SAG immunoprecipitates (Figure S4F).
Thus, SAG-SKP1-CUL1-FBXW7 could form an active E3 ubiqui-
tin ligase in vivo that regulates cellular levels of NF1 by pro-
moting its ubiquitination and degradation. To a lesser extent,
CUL-5 appears to be also involved in NF1 degradation (Figuresits two mutants were cotransfected into H1299 cells. Cells were treated with
r HA, or for (F) IP with HA and IB with NF1 Ab to show ubiquitination of both
direct IB (bottom).
F E3 was prepared by FLAG bead IP using 293 cells transfected with CUL1 and
g FLAG-NF1-C into 293 cells, followed by FLAG-bead IP and 3xFLAG peptide
ing ATP, Myc-Ub, E1, and E2. E2 was omitted in some reactions. The reaction
tes nonspecific bands. See also Figure S4.
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Figure 5. FBXW7 and SAG Shorten NF1 Protein Half-Life
(A and B) FBXW7 shortens, but FBXW7DF extends the NF1 protein half-life: The 293 cells were transfected and treated with CHX (cycloheximide) to block new
protein synthesis and with TPA to trigger degradation. Samples were harvested for IB. Densitometry quantification was performed with ImageJ.
(C) SAG further shortens NF1 protein half-life: FLAG-NF1-C was cotransfected with FBXW7, with or without FLAG-SAG into 293 cells. Cells were harvested after
CHX treatment for IB and quantified by ImageJ.
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to an E3 complex with SOCS-SAG (Kamura et al., 2004).
SAG-FBXW7 Shortens NF1 Protein Half-Life and Is
Required for Serum- or Mitogen-Induced
NF1 Ubiquitination and Degradation
We next determined whether FBXW7 shortens protein half-life of
NF1, and whether SAG could further accelerate it. The protein
half-life of transfected NF1-C was 2 hr upon TPA stimulation,
which was reduced to 1 hr when cotransfected with wt
FBXW7 (Figure 5A), but extended to 4 hr when cotransfected
with an F-box deleted dominant negative FBXW7 mutant (Fig-
ure 5B). The protein half-life of two NF1 mutants was much
extended under the same conditions (Figures S5A and S5B).
Moreover, cotransfection of SAG with FBXW7 further shortened
the protein half-life of NF1-C from 3 hr (FBXW7 alone) to 1.5 hr
(when combined) in the absence of TPA stimulation (Figure 5C).
We further determined the effect of FBXW7 on protein half-life of
endogenous NF1. Under normal growth conditions, endogenous
NF1 is relatively stable with a protein half-life much longer than
3 hr, regardless of FBXW7 status (Figure S5C). NF1 was, how-
ever, subject to mitogen-induced reduction in an FBXW7 de-
pendent manner. In serum-starved FBXW7/ DLD1 cells
(Rajagopalan et al., 2004), serum addition had no effect on
NF1 levels up to 120 min. In contrast, serum addition to starved
FBXW7+/+ DLD-1 cells induced a rapid elimination of NF1 within
15 min, which lasted up to 120 min before it started to recover
(Figure 5D, top). Likewise, the protein half-life of endogenous
NF1 after exposure to TPA was about 30 min, which was ex-
tensively extended in FBXW7/ cells (Figure 5D, bottom). No
change at the level of p120RasGAP was observed, regardless of
FBXW7 status (Figure 5D). We further confirmed that FBXW7-
dependent NF1 reduction was via the ubiquitin-proteasome
pathway, because concurrent MG-132 treatment blocked NF1
degradation, along with accumulation of ubiquitinated NF1 in
FBXW7+/+ cells, but not in FBXW7/ cells (Figure 5E). Finally,
we found that both SAG and CUL1/5 were involved in controlling
the NF1 turn-over. The Nf1 half-life was much extended in
Sag/MEF cells, as compared to Sag+/+ cells under the condi-
tions of serum starvation, followed by serum addition to trigger
Nf1 degradation (Figure 5F). Similarly, TPA-induced NF1 degra-
dation was much delayed upon siRNA knockdown of either
CUL1 or CUL5 (Figure 5G). Thus, NF1 is a physiological
substrate of SAG-CUL1-FBXW7 (and possibly a SAG-CUL5
based E3 ligase) for targeted degradation.
Simultaneous Deletion of Nf1 Rescues the Vascular
Defects in Sag–/– ES Cells and Embryos
We next attempted to define the physiological importance of Nf1
accumulation upon Sag disruption in endothelial differentiation
of ES cells and vascular development of embryos. We reasoned
that if Nf1 accumulation inhibits endothelial differentiation of(D and E) FBXW7-dependent degradation of endogenous NF1. DLD-1 cells with
addition. Cells were then harvested for IB (D, top). Cells were treated with TPA a
24 hr, followed by serum addition in combination with MG-132. Cells were harve
(F and G) Inactivation of Sag or CUL1/5 extended Nf1 protein half-life: MEFs (Sag+
were harvested at indicated periods for IB. * denotes nonspecific band (F). H1299
siRNA. Cells were treated with TPA (10 nM) 48 hr later for indicated periods and
DevelopmentaEBs by inhibiting Ras/Erk activation, then simultaneous deletion
of Nf1 would restore the formation of cystic EBs in the Sag/
background. We generated Sag/Nf1 double null ES clones
from blastocysts obtained by the mating of Sag+/ and Nf1+/
mice (Zhu et al., 2005). Among 64 ES lines established, we iden-
tified a single clone (ISG8) with the Sag/;Nf1/ genotype.
However, this clone did not grow well and was readily attached
onto the Petri dish during suspension culture for differentiation,
leading to much fewer numbers of embryoid bodies, although
we did observe the formation of cEBs at a rate comparable to
that of wild-type (Figure 6A) with full restoration of Ras activity
(Figure S6B). We then focused our attention to three indepen-
dent Sag/;Nf1+/ ES cell lines and found that all three were
able to undergo endothelial differentiation to form cystic EBs,
although the frequency was relatively lower than that of wild-
type (Figures 6A and 6C, two clones, A1 and A10 were shown).
The blood island structures with endothelial lining were apparent
in these rescued cEBs (Figure 6B), indicating that heterozygous
loss of Nf1 is sufficient to rescue the defect in endothelial differ-
entiation caused by Sag inactivation. We further confirmed that
the Nf1 status on the Sag+/+ background did not affect endothe-
lial differentiation, because both Nf1+/ and Nf1/ ES cells are
capable of forming cEBs (Figure S6C). We next determined if
Ras activity was also rescued upon Nf1 inactivation and found
that although Sag/;Nf1+/+ EBs showed a high level of Nf1
with a undetectable Ras activity (Figure 6D, lane 1),
Sag/;Nf1+/ EBs had a significant lower level of Nf1, but
a high level of activated Ras, similar to that seen in wild-type
EBs (Figure 6D, lanes 2 versus 3). These results suggested that
loss of one Nf1 allele is sufficient to reduce abnormally high
levels of Nf1 (caused by Sag disruption) to a level that permits
cystic EB formation during ES cell differentiation. Taken
together, our results demonstrated that Ras inactivation, as
a result of Nf1 accumulation upon Sag disruption, is the major
cause for the failure of Sag/ ES cells to undergo endothelial
differentiation.
We then determined whether simultaneous deletion of Nf1
would rescue vascular defects in Sag/ embryos (Figure 1D)
by crossing of Sag+/mice with Nf1+/mice. Although homozy-
gous deletion of Nf1 caused embryonic lethality by E13.5 due to
cardiac defects, mutant embryos appeared normal through
E10.5 (Brannan et al., 1994; Jacks et al., 1994). We examined
the blood vessel networks in head areas of E10.5 embryos
with four genotypes, using CD31 whole-mount staining (Fig-
ure 6E). Whereas Sag/;Nf1+/+ brains showed reduced primary
vascular networks with missing major trunk vessels, Sag+/+;-
Nf1/ brains showed relatively normal vasculature, similar to
that of Sag+/+;Nf1+/+. Significantly, the vasculature in the head
areas of Sag/;Nf1/ embryos showed a partial restoration
with reappearance of some trunk blood vessels (Figure 6E),
even though these Sag/;Nf1/ embryos remained growth-
retarded (Figures 6E and 6F). Furthermore, CD31-positiveor without FBXW7 deleted were serum starved for 24 hr, followed by serum
nd CHX, and harvested for IB (D, bottom). DLD-1 cells were serum starved for
sted 15 min later for IB (E).
/+ or Sag/) were serum starved up to 48 hr, followed by serum addition. Cells
cells were transfected with siRNA targeting CUL1 or CUL5, along with control
harvested for IB (G). See also Figure S5.
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Figure 6. Rescuing Sag–/– Defective Phenotypes by Simultaneous Deletion of Nf1
(A–C) Heterozygous deletion ofNf1 rescued the differentiation defects. ES cells underwent endothelial differentiation for 12 days andwere photographed to show
cystic EBs (A, arrows). The EBs were whole-mounted with CD31, and counterstained with eosin (2003) (B). The proportion of cEBs in a total of 300 EBs was
plotted, mean ± SD (n = 3) (C).
(D) Heterozygous deletion of Nf1 rescued Ras activity. EBs formed after differentiation for 5 days were measured for Ras activity by a pull-down assay, and IB for
total Ras, Nf1, and Sag. SE, short exposure; LE, longer exposure.
(E)Nf1 deletion partially rescued vascular defects in embryonic brains: Sag+/;Nf1+/mice were intercrossed, embryos at E10.5 were dissected and subjected to
CD31 whole-mount staining. Representative embryos of four genotypes were photographed. Scale bar represents 3 mm.
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that covered the entire neuroepithelium, whereas only residual
CD31-positive cells were found in the Sag/ embryos (arrows,
Figure 6F). Importantly, the chain-like structure formed by
CD31-positive endothelial cells was partially restored by both
Nf1 heterozygous and homozygous mutations (Figures 6F and
6H).
Consistent with our previous observation that SAG is an anti-
apoptotic protein in cell culture settings (Duan et al., 1999; Sun
et al., 2001), we observed that Sag disruption caused a wide-
spread apoptosis in embryos evidenced by cleaved caspase 3
staining (Figure 6F). To rule out the possibility that excessive
apoptosis observed in Sag-deficient embryos could potentially
exert nonspecific effects on normal development of endothelial
cells, we further analyzed control and Sag-deficient embryos at
earlier stages. At E9.5, compared to controls, Sag-deficient em-
bryos exhibited relatively normal morphology with only a minor
increase in apoptosis within developing nervous system (Fig-
ure 6G). However, the number of CD31-positive endothelial
cells was greatly reduced in Sag-deficient embryos (arrows,
Figure 6G). Particularly, compared to control embryos, Sag-
deficient embryos only contained <10% of CD31-positive endo-
thelial cells in the head areas (Figure 6I). Strikingly, this defect
was significantly rescued by loss of one or two alleles of Nf1
(arrows, Figures 6G and 6I). When comparing the relative
number of CD31-positive endothelial cells at E9.5 and E10.5
among control, Sag single, and Sag/Nf1 double mutant em-
bryos, we found that CD31-positive endothelial cells in all the
mutant embryos, albeit at a much lower level, expanded propor-
tionally from E9.5 to E10.5, as compared to those in controls
(Figure 6J). Taken together, our studies, using both in vitro ES
cells and in vivo embryos, suggest that Sag-mediated Nf1 degra-
dation is critical for the genesis of endothelial cells in the vascular
system. This notion was further supported by the fact that CD31-
positive endothelial cells in Sag-deficient embryos at both E9.5
and E10.5 stages did not colocalize with caspase-3 positive cells
(Figures 6F and 6G), excluding the involvement of apoptosis.Nf1 Inactivation Partially Rescues Apoptotic, but Not
Proliferative, Defects in Developing Sag-Deficient
Neural Precursor Cells
To further determine genetic interaction between Sag and Nf1
in vivo,we studiedNf1-dependent Sag function in the developing
nervous system, as 40%–80% of NF1 children exhibit learning
deficits (Hyman et al., 2005). During development, the onset of
neurogenesis in the neocortex occurs at the basal surface of
the neuroepithelium at E10.5 (Farkas and Huttner, 2008; Go¨tz
and Huttner, 2005). We found that neuronal differentiation, re-
vealed by Tuj1 expression, was not significantly different
between control andSag-deficient embryoswith orwithout addi-(F andG) Deletion ofNf1 partially rescued a reduction of endothelial cells inSag de
embryos were stained with CD31, cleaved caspase 3, and DAPI. Images were ca
middle panels) as well as for trunk areas (bottom panels). Scale bar represents 1
(H and I) Quantification of CD31 positive cells in the head areas at E10.5 (H) and E9
fold change relative to the number of CD31 positive cells in Sag+/+ Nf1+/+, which
(J) The percentage of CD31 positive cells in head areas of control andmutant emb
the total number of DAPI positive cells. (mean ± SEM, n = 3). See also Figure S6
Developmentational Nf1 mutations (Figures 7A and 7B). These results indicate
that Sag/ neural precursor cells in the neocortex undergo
neuronal differentiation according to a normal developmental
schedule, albeit in overall growth-retarded embryos. We next
examined whether there are proliferation defects in Sag/
neural precursor cells. During cell cycle, neural precursor cells
undergo DNA replication (S phase) in the basal part of the neuro-
epithelium (Farkas and Huttner, 2008), which were labeled by
a single BrdU pulse (Figure 7C, upper left). The nuclei of neural
precursor cells migrate apically through G2 phase to undergo
M phase in apical position along the ventricle, which were re-
vealed by an M phase marker, phospho-histone H3 (PH3) (Fig-
ure 7C, bottom left). Strikingly, little or no BrdU- or PH3-positive
neural precursor cells were identified in the Sag/ neocortex
(Figure 7C). More importantly, none of the defects in cell cycle
progression was rescued by Nf1 inactivation (Figure 7C). Thus,
Sag-deficient neural precursor cells in the developing neocortex
exhibited severe defects in entering S and M phases of the cell
cycle in an Nf1-independent manner. Consequently, compared
to control neocortex, the number of neural precursor cells
labeled by Ki67 expression was significantly reduced in the
Sag/ neuroepithelium, consistent with the fact that these cells
had proliferation defects (Figures 7D and 7E). Given thatNf1 defi-
ciency does not rescue cell-cycle progression defects in Sag/
neural precursor cells, we unexpectedly observed a significant
level of rescue of Ki67-positive neural precursor cells upon Nf1
deletion (Figures 7D and 7E). We, therefore, determined whether
apoptosis additionally contributed to Nf1-dependent reduction
of neural precursor cells in Sag/ neocortex. Although control
neocortex had little or no caspase3-positive apoptotic cells,
nearly 40% of Sag/ cells in E10.5 neocortex were undergoing
apoptosis, which was significantly rescued by Nf1 inactivation in
a dose-dependent manner (Figures 7D and 7F). In addition to the
developing brain, Nf1 inactivation also partially rescued
apoptosis in the Sag-deficient spinal cord (arrows, Figure 7G),
though apoptosis in surrounding mesoderm-derived tissues
was not affected (Figure 7G). Moreover, neuronal apoptosis of
Sag/ E9.5 embryos could also be rescued by Nf1 deletion (Fig-
ure 6G; Figure S6D). Taken together, our observations demon-
strate that during neocortical development, Sag plays critical
roles in regulating apoptosis and cell cycle progression in an
Nf1-dependent and Nf1-independent manner, respectively.
Furthermore, Nf1-dependent Sag function in suppressing apo-
ptosis is specifically required for developing nervous system,
but not for surrounding mesenchymal tissues.DISCUSSION
Despite Sag being dispensable during development in
Drosophila and C. elegans (Moore and Boyd, 2004; Reynoldsficient embryos at E10.5 (F) and E9.5 (G). Sagittal sections of control andmutant
ptured at low and high-magnifications for cranial neuroepithelial cells (top and
00 mm.
.5 (I). The data were normalized to the total number of DAPI and represented as
were set to 1 (mean ± SEM, n = 3).
ryos at E9.5 and E10.5. The number of cells expressing CD31was normalized to
.
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Figure 7. Inactivation of Nf1 Partially Rescued Apoptotic Phenotype but Not Proliferation Defects in Developing Sag–/– Neural Precursor
Cells
(A) Neuronal differentiation detected by Tuj-1 (an early neuronal marker). Sagittal sections of embryonic brains (E10.5) with different genotypes were stained with
Tuj-1 and DAPI. Scale bar represents 100 mm. A, apical; B, basal.
(B) Quantification of Tuj-1 positive cells in the neuroepithelium were normalized to total DAPI positive cells (mean ± SEM, n = 3).
(C) Nf1 deletion failed to rescue proliferation defects in Sag/ neural precursor cells. Brain sections were stained with BrdU (an S phase marker) or Phospho-
histone H3 (PH3, an M phase marker) as well as DAPI. Scale bar represents 100 mm.
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mouse development. Sag disruption causes embryonic lethality
at E11.5–12.5, which is associated with severe developmental
defects including those in the vascular and nervous system.
Because SCF E3 ligases are essential for many developmental
processes (Petroski and Deshaies, 2005), it is not surprising
that Sag, one of the two Rbx/Roc family members essential for
E3 ligase activity, plays critical roles in many aspects of embry-
onic development. Although accumulation of many critical Sag/
SCF-targeted substrates could contribute to severe develop-
mental defects observed in Sag/ embryos, our biochemical
and genetic experiments indicate a causal involvement of Nf1,
which, upon accumulation as a result of Sag disruption, inacti-
vates Ras-Mapk signals to block endothelial differentiation and
induce apoptosis in the nervous system.
The RAS-MAPK signaling pathway is actively involved in cell
proliferation, angiogenesis, and tumorigenesis (Dhillon et al.,
2007a; Kranenburg et al., 2004) as well as endothelial specifica-
tion of VEGFR2-expressing vascular progenitor cells (Kawasaki
et al., 2008). Here we showed that active Ras/Erk signals are
also required for endothelial differentiation of mouse ES cells.
Blockade of this pathway by inhibitors of RAS (FTI-277) or
MEK (PD98059) repressed ES cell differentiation into endothelial
cells to form blood islands. We further showed in vivo that re-
duced Ras/Erk activation was associated with reduced angio-
genesis and decreased proliferation in teratomas derived from
Sag/ ES cells. Our mechanistic study linked Ras inactivation,
upon Sag disruption, to accumulation of Nf1, a naturally occur-
ring Ras inhibitor (Cichowski and Jacks, 2001).
Our study also defined SAG-SKP1-CUL1-FBXW7 as a physio-
logical E3 ligase for targeted ubiquitination and degradation of
NF1. First, NF1 contains an evolutionarily conserved FBXW7
binding motif at the C terminus (codons 2755–2758), which is
required for FBXW7-NF1 binding and NF1 ubiquitination.
Second, SAG-CUL1-FBXW7-NF1 forms a complex in vivo that
promotes NF1 ubiquitination. Third, FBXW7 shortens NF1 pro-
tein half-life in a binding motif dependent manner, which is
further promoted by SAG. Fourth, ubiquitination of exogenously
expressed NF1-C is promoted by FBXW7-CUL1, but inhibited
by siRNA knockdown of CUL1 or genetic deletion of FBXW7.
Finally and most importantly, endogenous FBXW7 binds to
endogenous NF1 under physiological conditions and SAG-
CUL1-FBXW7 is required for ubiquitination and degradation of
endogenous NF1 uponmitogen stimulation. Our study also dem-
onstrates that SAG could form an active E3 complex with SKP1,
FBXW7, and CUL1, in addition to well-known CUL5 (Kamura
et al., 2004), for targeted degradation of NF1.
FBXW7 is a p53-dependent haploinsufficient tumor sup-
pressor (Kimura et al., 2003; Mao et al., 2004). Similar to Sag
disruption, Fbxw7 gene ablation also causes embryonic lethality
at E10.5–E11.5 with remarkable abnormalities in vascular devel-
opment in the brain and yolk sac (Tetzlaff et al., 2004; Tsune-
matsu et al., 2004). These phenotypic similarities suggested(D–F) Nf1 deletion partially rescued neural apoptosis: Sagittal sections of embryo
100 mm. The number of cells expressing Ki67 and caspase3 was normalized to the
(G) Nf1 deletion partially rescued apoptosis in the spinal cord, but not surround
DAPI. Arrows point to spinal cord. Scale bar represents 100 mm.
Developmentathat Sag and Fbxw7 might have a similar function, such as pre-
venting Nf1 accumulation, during vascular development. How-
ever, unlike Fbxw7 whose deletion caused accumulation of
Notch-1 and Notch-4 (Masuda et al., 2010; Tetzlaff et al., 2004;
Tsunematsu et al., 2004), we found that neither Notch-1 nor
Notch-4 was accumulated in Sag/ ES, EB, or embryos (data
not shown), suggesting that accumulation of Notch family pro-
teins do not contribute to observed defects in Sag/ ES cells
and embryos. Instead, we showed a causal involvement of Nf1
in some aspects of vascular and neural development, regulated
by Sag. First, Sag is required for endothelial cell differentiation,
which is Nf1 dependent. Second, Sag plays an essential role in
suppressing apoptosis during embryogenesis, with a partial
involvement of Nf1 in neural precursor cells in developing brains
and spinal cords, but not in mesoderm-derived tissues. Third,
despite the presence of a significant number of neural precursor
cells in Sag/ neocortex, these Ki67-positive precursor cells
completely lack the ability to undergo DNA replication and
mitosis, which is completely independent of Nf1. It will be inter-
esting to determine the specific stage(s) in which Sag/ neural
precursor cells are arrested during cell cycle. These observa-
tions suggest that Nf1-independent apoptosis and cell cycle
failure, potentially as a result of accumulation of other critical
Sag substrates, could be the major cause for growth retarded
and lethal phenotypes observed in Sag/;Nf1/ embryos
with an embryonic life not extended beyond E11.5–12.5. Never-
theless, our genetic rescue data, by demonstrating that Nf1
inactivation rescued vascular defects, particularly at earlier
developmental stages when Sag deficiency causes no overt
morphological defects, strongly argue that genetic interaction
between Nf1 and Sag is specific and primary to vascular devel-
opment and not secondary to overall developmental retardation.
Furthermore, it is worth noting that despite the presence of
excessive and widespread apoptosis at E10.5, CD31-positive
endothelial cells expanded proportionally from E9.5 to E10.5 in
Sag-deficient embryos compared to controls. This observation
further supports the notion that Sag/Nf1 regulatory network
controls the generation of CD31-positive endothelial cells, but
not subsequent proliferation or apoptosis.
In summary, our study demonstrates an in vivo physiological
function of Sag in regulation of vascular and neural development
by modulating Ras-Mapk signaling pathway through targeted
degradation of Nf1. Upon induction by different stimuli (Duan
et al., 1999; Gu et al., 2007a; Tan et al., 2008), SAG recruits
FBXW7 and CUL1 to promote ubiquitination and degradation
of NF1, thus activating RAS-ERK signals to induce differentiation
and proliferation, and to suppress apoptosis during vascular
and neural development, respectively (see graphical abstract).
Thus, under physiological conditions, SAG regulates NF1 levels
to maintain active RAS/ERK signals for effective vascular and
neural development. However, under pathological condition,
such as in cancer, SAG, which is overexpressed with a poor
patient prognosis (Jia et al., 2010; Sasaki et al., 2001), wouldnic brains were stained with Ki67, caspase 3, and DAPI. Scale bar represents
total number of DAPI positive cells (***p < 0.0001, mean ± SEM, n = 3) (E and F).
ing mesenchymal cells. Embryonic sections were stained with caspase 3 and
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et al., 1999; Gu et al., 2007b; Sun et al., 2001). SAG, therefore,
could be a valid anticancer and antiangiogenesis target (Jia
et al., 2010; Nalepa et al., 2006; Sun, 2006; Wei and Sun,
2010). Moreover, 40%–80% of individuals with NF1 have cogni-
tive deficits, which are at least partially caused by loss of one
allele of the NF1 gene (haploinsufficiency) in the brain (Costa
et al., 2002; Cui et al., 2008; Hyman et al., 2006). Thus, targeting
the SAG/FBXW7 E3 may provide an attractive therapeutic
strategy to increase NF1 protein levels for treating NF1-associ-
ated diseases caused by haploinsufficiency.
EXPERIMENTAL PROCEDURES
Generation and Maintenance of ES Cell Lines with Sag and/or Nf1
Disruption
Blastocysts were isolated from intercrossing of Sag+/ mice or Sag+/;Nf1+/
mice, and placed in culture on irradiated mouse embryonic feeder cells in high
glucose DMEM (Invitrogen, Carlsbad, CA) supplemented with 15% FBS
(Harlan, Indianapolis, IN), 0.1 mM b-mercaptoethanol (Sigma, St. Louis, MO),
103 U/ml LIF (ESGRO, Millipore), 25 mM PD98059 (Sigma) and penicillin/
streptomycin. Inner cell mass outgrowths were trypsinized and passaged until
ES cell lineswere established in 35mmcell culture dishes (Hughes et al., 2007).
Whole-Mount Immunostaining on Yolk Sac and Embryos
Whole-mount CD31 immunostaining was performed on E9.5 and E10.5 yolk
sacs and embryos (Shen et al., 2005). Briefly, embryos or yolk sacs were fixed
in 4% PFA/PBS, dehydrated by methanol, quenched by H2O2, and blocked in
4% BSA. The samples were stained by incubating with anti-CD31 (rat mono-
clonal MEC13.3, BD Biosciences) at 4C overnight, followed by peroxidase-
conjugated secondary antibodies. The embryos were developed in 0.25%
DAB with H2O2 in PBS, and photographed on a dissecting microscope (model
S6D; Leica) with a progressive 3CCD camera (Sony).
Endothelial Differentiation of ES Cells and Whole-Mount Staining
of Embryoid Bodies
Single suspendedmouse ES cells were plated at density of 13 106 cells/10 cm
Petri dish containing 15%DMEM in the absence of LIF. Cells were cultured for
up to 13 days with media change every other day. Embryoid bodies were first
fixed in the 4% PFA, blocked with 3%milk and 0.1% Triton X-100 in PBS, and
incubated with CD31 antibody overnight. After washing, the samples were
incubated with secondary antibody overnight. Color was developed using
DAB. The samples were then dehydrated, embedded, and sectioned. The
sections were counterstained with Eosin-Y.
Immunofluorescence
Paraffin sections were deparaffinized, rehydrated, and analyzed by immuno-
fluorescence (Wang et al., 2009; Zhu et al., 2001). Briefly, sections were incu-
bated with primary antibodies in blocking solution overnight. The antibodies
used are as follows: Ki 67 (1:500, mouse, BD Biosciences), Tuj-1 (1:500,
Rabbit, Covance), Cleaved Caspase3 (1:500, Rabbit, Cell signaling), Phospho-
histone H3 (1:500, Rabbit, Abcam), BrdU (1:500, Rat, Abcam), and CD31
(1:200, Mouse, Dako). The secondary antibodies were conjugates of Alexa
Fluor 488 or Alexa Fluor 555 (1:500, Invitrogen). DAPI (1:1000, Invitrogen) was
used as nuclear counter staining. Sections were examined under a fluo-
rescence microscope (Olympus).
Statistical Analysis
The paired Student’s t test was used for statistical analysis, using SAS soft-
ware for two paired samples. A mixed model was fit to the tumor volumes
(excluding mice with no tumors). Presence or absence of Sag knockout was
included as a fixed effect. ES cell line was included as a random effect in the
model to account for correlation between observations within a cell line. An
F-test from the mixed model fit was used to test whether the mean value for
tumors from cell lines with Sag knockout was the same as that for the tumors
with wild-type Sag.1074 Developmental Cell 21, 1062–1076, December 13, 2011 ª2011SUPPLEMENTAL INFORMATION
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